Literature DB >> 17579659

[11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling?

Alexander Hammers1, Prasan Panagoda, Rolf A Heckemann, Wolfgang Kelsch, Federico E Turkheimer, David J Brooks, John S Duncan, Matthias J Koepp.   

Abstract

Reduced signal on [(11)C]]flumazenil (FMZ) positron emission tomography (PET) is associated with epileptogenic foci. Linear correlations within individuals between parametric and nonparametric images of FMZ binding have been shown, and various methods have been used, without comparison of diagnostic usefulness. Using hippocampal sclerosis (HS) as a test case, we formally compare the diagnostic yield of parametric images obtained either with a parent tracer arterial plasma input function and spectral analysis (yielding volume-of-distribution (VD) images), or with an image-based input function and the simplified reference tissue model (binding potential images, BP-SRTM) with the diagnostic yield of semiquantitative-integrated (ADD) images from 10 to 20 or 20 to 40 mins (ADD1020 and ADD2040). Dynamic 90-min [(11)C]FMZ PET datasets and arterial plasma input functions were available for 15 patients with medically refractory medial temporal lobe epilepsy (TLE) and histologically verified unilateral HS and for 13 control subjects. SPM2 was used for analysis. ADD1020 and ADD2040 images showed decreased FMZ uptake ipsilateral to the epileptogenic hippocampus in 13/15 cases; 6/13 had bilateral decreases in the ADD1020 analysis and 5/13 in the ADD2040 analysis. BP-SRTM images detected ipsilateral decreases in 12/15 cases, with bilateral decreases in three. In contrast, VD images showed ipsilateral hippocampal decreases in all 15 patients, with bilateral decreases in three patients. Bilateral decreases in the ADD images tended to be more symmetrical and in one case were more marked contralaterally. Full quantification with an image-independent input should ideally be used in the evaluation of FMZ PET; at least in TLE, intrasubject correlations do not predict equivalent clinical usefulness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579659     DOI: 10.1038/sj.jcbfm.9600515

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  11 in total

1.  GABAA Receptors in the Mongolian Gerbil: a PET Study Using [18F]Flumazenil to Determine Receptor Binding in Young and Old Animals.

Authors:  M Kessler; M Mamach; R Beutelmann; M Lukacevic; S Eilert; P Bascuñana; A Fasel; F M Bengel; J P Bankstahl; T L Ross; G M Klump; G Berding
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

2.  Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans.

Authors:  Jim Fm Myers; Robert A Comley; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

3.  Focal decreases of cortical GABAA receptor binding remote from the primary seizure focus: what do they indicate?

Authors:  Csaba Juhász; Eishi Asano; Aashit Shah; Diane C Chugani; Carlos E A Batista; Otto Muzik; Sandeep Sood; Harry T Chugani
Journal:  Epilepsia       Date:  2008-07-14       Impact factor: 5.864

4.  [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein.

Authors:  Femke E Froklage; Stina Syvänen; N Harry Hendrikse; Marc C Huisman; Carla Fm Molthoff; Yoshihiko Tagawa; Jaap C Reijneveld; Jan J Heimans; Adriaan A Lammertsma; Jonas Eriksson; Elizabeth Cm de Lange; Rob A Voskuyl
Journal:  EJNMMI Res       Date:  2012-03-28       Impact factor: 3.138

5.  Test-retest reproducibility of quantitative binding measures of [11C]Ro15-4513, a PET ligand for GABAA receptors containing alpha5 subunits.

Authors:  Colm J McGinnity; Daniela A Riaño Barros; Lula Rosso; Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; Rainer Hinz; Federico E Turkheimer; Matthias J Koepp; Alexander Hammers
Journal:  Neuroimage       Date:  2017-03-11       Impact factor: 6.556

6.  Periventricular [(11)C]flumazenil binding for predicting postoperative outcome in individual patients with temporal lobe epilepsy and hippocampal sclerosis.

Authors:  Josiane Yankam Njiwa; Sandrine Bouvard; Hélène Catenoix; François Mauguiere; Philippe Ryvlin; Alexander Hammers
Journal:  Neuroimage Clin       Date:  2013-09-03       Impact factor: 4.881

7.  Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study.

Authors:  Ling Feng; Claus Svarer; Karine Madsen; Morten Ziebell; Agnete Dyssegaard; Anders Ettrup; Hanne Demant Hansen; Szabolcs Lehel; Stig Yndgaard; Olaf Bjarne Paulson; Gitte Moos Knudsen; Lars Hageman Pinborg
Journal:  Biomed Res Int       Date:  2016-03-31       Impact factor: 3.411

8.  Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis.

Authors:  Femke E Froklage; Andrey Postnov; Maqsood M Yaqub; Esther Bakker; Ronald Boellaard; N Harry Hendrikse; Emile Fi Comans; Robert C Schuit; Patrick Schober; Demetrios N Velis; Jack Zwemmer; Jan J Heimans; Adriaan A Lammertsma; Rob A Voskuyl; Jaap C Reijneveld
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-19       Impact factor: 6.200

9.  The Evaluation of Dynamic FDG-PET for Detecting Epileptic Foci and Analyzing Reduced Glucose Phosphorylation in Refractory Epilepsy.

Authors:  Yongxiang Tang; Jeih-San Liow; Zhimin Zhang; Jian Li; Tingting Long; Yulai Li; Beisha Tang; Shuo Hu
Journal:  Front Neurosci       Date:  2019-01-09       Impact factor: 4.677

10.  Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [¹¹C]MePPEP.

Authors:  Daniela A Riaño Barros; Colm J McGinnity; Lula Rosso; Rolf A Heckemann; Oliver D Howes; David J Brooks; John S Duncan; Federico E Turkheimer; Matthias J Koepp; Alexander Hammers
Journal:  Neuroimage       Date:  2014-04-13       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.